BG
ARCT icon

Bellevue Group’s Arcturus Therapeutics ARCT Stock Holding History

Bellevue Group’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-39,550
Closed -$623K – 178
2022
Q2 		$623K Sell
39,550
-1,350
-3% -$26.5K 0.01% 146
2022
Q1 		$1.1M Sell
40,900
-700
-2% -$17.9K 0.01% 148
2021
Q4 		$1.54M Buy
41,600
+7,100
+21% +$289K 0.02% 150
2021
Q3 		$1.65M Buy
+34,500
New +$1.55M 0.02% 153

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Bellevue Group's ARCT Position: Q3 2022 in Review

Bellevue Group sold out of Arcturus Therapeutics (ARCT) in Q3 2022, closing a stake of 39,550 shares — an estimated $623K sold.

Bellevue Group first reported a position in ARCT in Q3 2021 and held it in 4 quarters. The position peaked at $1.65M in Q3 2021. 116 funds tracked by Wall St. Rank hold ARCT as of Q3 2022.

  • Bellevue Group reported no remaining Arcturus Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Bellevue Group sold 39,550 Arcturus Therapeutics shares in Q3 2022, an estimated $623K.
  • Bellevue Group first reported a position in Arcturus Therapeutics in Q3 2021 and held it in 4 quarters.
  • Bellevue Group's Arcturus Therapeutics position peaked at $1.65M in Q3 2021.
  • 116 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2022.

Based on Bellevue Group's 13F filing for Q3 2022, filed 14 Nov 2022.